124 related articles for article (PubMed ID: 23379599)
21. Safety and efficacy of administering abobotulinumtoxinA through a single injection point when treating lateral periocular rhytides.
Kiripolsky MG; Goldman MP
J Cosmet Dermatol; 2011 Sep; 10(3):232-4. PubMed ID: 21896136
[TBL] [Abstract][Full Text] [Related]
22. Pilot study evaluating the safety of intradetrusor injections of botulinum toxin type A: investigation of generalized spread using single-fiber EMG.
Schnitzler A; Genet F; Durand MC; Roche N; Bensmail D; Chartier-Kastler E; Denys P
Neurourol Urodyn; 2011 Nov; 30(8):1533-7. PubMed ID: 21661038
[TBL] [Abstract][Full Text] [Related]
23. Comparing the clinical attributes of abobotulinumtoxinA and onabotulinumtoxinA utilizing a novel contralateral Frontalis model and the Frontalis Activity Measurement Standard.
Nestor MS; Ablon GR
J Drugs Dermatol; 2011 Oct; 10(10):1148-57. PubMed ID: 21968665
[TBL] [Abstract][Full Text] [Related]
24. Botulinum toxin injection of both sides of the face to treat post-paralytic facial synkinesis.
Choi KH; Rho SH; Lee JM; Jeon JH; Park SY; Kim J
J Plast Reconstr Aesthet Surg; 2013 Aug; 66(8):1058-63. PubMed ID: 23683725
[TBL] [Abstract][Full Text] [Related]
25. The Facial Platysma and Its Underappreciated Role in Lower Face Dynamics and Contour.
de Almeida ART; Romiti A; Carruthers JDA
Dermatol Surg; 2017 Aug; 43(8):1042-1049. PubMed ID: 28394862
[TBL] [Abstract][Full Text] [Related]
26. A Randomized, Double-Blind Trial to Investigate the Equivalence of IncobotulinumtoxinA and OnabotulinumtoxinA for Glabellar Frown Lines.
Kane MA; Gold MH; Coleman WP; Jones DH; Tanghetti EA; Alster TS; Rohrer TE; Burgess CM; Shamban AT; Finn E
Dermatol Surg; 2015 Nov; 41(11):1310-9. PubMed ID: 26509943
[TBL] [Abstract][Full Text] [Related]
27. [Facial anatomy and botulinum toxin: the muscular balances].
Trevidic P; Cauchois R; Ingallina F
Ann Dermatol Venereol; 2009 May; 136 Suppl 4():S61-6. PubMed ID: 19576487
[TBL] [Abstract][Full Text] [Related]
28. A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines.
Moers-Carpi M; Dirschka T; Feller-Heppt G; Hilton S; Hoffmann K; Philipp-Dormston WG; Rütter A; Tan K; Chapman MA; Fulford-Smith A
J Cosmet Laser Ther; 2012 Dec; 14(6):296-303. PubMed ID: 23057624
[TBL] [Abstract][Full Text] [Related]
29. Muscle structure and stiffness assessment after botulinum toxin type A injection. A systematic review.
Mathevon L; Michel F; Decavel P; Fernandez B; Parratte B; Calmels P
Ann Phys Rehabil Med; 2015 Dec; 58(6):343-50. PubMed ID: 26602437
[TBL] [Abstract][Full Text] [Related]
30. Decreased tear expression with an abnormal Schirmer's test following botulinum toxin type A for the treatment of lateral canthal rhytides.
Matarasso SL
Dermatol Surg; 2002 Feb; 28(2):149-52. PubMed ID: 11860426
[TBL] [Abstract][Full Text] [Related]
31. Hourglass deformity after botulinum toxin type A injection.
Guyuron B; Rose K; Kriegler JS; Tucker T
Headache; 2004 Mar; 44(3):262-4. PubMed ID: 15012666
[TBL] [Abstract][Full Text] [Related]
32. The use of botulinum toxin type A in cosmetic facial procedures.
Jaspers GW; Pijpe J; Jansma J
Int J Oral Maxillofac Surg; 2011 Feb; 40(2):127-33. PubMed ID: 20965695
[TBL] [Abstract][Full Text] [Related]
33. Glabellar contraction patterns: a tool to optimize botulinum toxin treatment.
de Almeida AR; da Costa Marques ER; Banegas R; Kadunc BV
Dermatol Surg; 2012 Sep; 38(9):1506-15. PubMed ID: 22804914
[TBL] [Abstract][Full Text] [Related]
34. Botulinum Toxin and Muscle Atrophy: A Wanted or Unwanted Effect.
Durand PD; Couto RA; Isakov R; Yoo DB; Azizzadeh B; Guyuron B; Zins JE
Aesthet Surg J; 2016 Apr; 36(4):482-7. PubMed ID: 26780946
[TBL] [Abstract][Full Text] [Related]
35. Consideration of muscle mass in glabellar line treatment with botulinum toxin type A.
Monheit G; Lin X; Nelson D; Kane M
J Drugs Dermatol; 2012 Sep; 11(9):1041-5. PubMed ID: 23135645
[TBL] [Abstract][Full Text] [Related]
36. Evolution of Facial Aesthetic Treatment Over Five or More Years: A Retrospective Cross-sectional Analysis of Continuous OnabotulinumtoxinA Treatment.
Carruthers A; Sadick N; Brandt F; Trindade de Almeida AR; Fagien S; Goodman GJ; Raspaldo H; Smith K; Darmody S; Gallagher CJ; Street J; Romagnano L
Dermatol Surg; 2015 Jun; 41(6):693-701. PubMed ID: 25973559
[TBL] [Abstract][Full Text] [Related]
37. A prospective, multicentre, randomized, double-blind, placebo-controlled trial of onabotulinumtoxinA to treat plantarflexor/invertor overactivity after stroke.
Dunne JW; Gracies JM; Hayes M; Zeman B; Singer BJ;
Clin Rehabil; 2012 Sep; 26(9):787-97. PubMed ID: 22308557
[TBL] [Abstract][Full Text] [Related]
38. Long-term treatment of glabellar rhytides using onabotulinumtoxina.
Dailey RA; Philip A; Tardie G
Dermatol Surg; 2011 Jul; 37(7):918-28. PubMed ID: 21575099
[TBL] [Abstract][Full Text] [Related]
39. Acute anxiety and depression induced by loss of sensation and muscle control after botulinum toxin A injection.
Brenner R; Madhusoodanan S; Korn Z; Spitzer M
South Med J; 1999 Jul; 92(7):738. PubMed ID: 10414488
[No Abstract] [Full Text] [Related]
40. Facial rejuvenation after intradermal botulinum toxin: is it really the botulinum toxin or is it the pricks?
Kapoor R; Shome D; Jain V; Dikshit R
Dermatol Surg; 2010 Dec; 36 Suppl 4():2098-105. PubMed ID: 21134041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
